BioVie Announces Completion Of Last Patient Treatment Visit In Phase 3 Trial Of NE3107 In Mild To Moderate Alzheimer's Disease
Portfolio Pulse from Benzinga Newsdesk
BioVie Inc. (NASDAQ:BIVI) has completed the last patient treatment visit in its Phase 3 trial of NE3107 for mild to moderate Alzheimer's Disease. The company expects to announce topline data in November/December 2023. The trial's results will be analyzed and submitted to the FDA for review. BioVie's President and CEO, Cuong Do, expressed optimism about the trial's outcome based on previous Phase 2 data.
September 26, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioVie's completion of the last patient treatment in its Phase 3 trial of NE3107 could potentially impact its stock positively, especially if the topline data, expected in November/December 2023, are favorable.
The completion of a Phase 3 trial is a significant milestone for any biotech company. If the topline data are positive, it could lead to FDA approval, which would significantly boost the company's prospects and potentially its stock price. However, the actual impact will depend on the data's specifics, which are yet to be released.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100